<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02196038</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00028221</org_study_id>
    <secondary_id>R01AG045551</secondary_id>
    <nct_id>NCT02196038</nct_id>
  </id_info>
  <brief_title>A Trial of Rehabilitation Therapy in Older Acute Heart Failure Patients</brief_title>
  <acronym>REHAB-HF</acronym>
  <official_title>REHAB-HF: A Trial of Rehabilitation Therapy in Older Acute Heart Failure Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      REHAB-HF: A Trial of Rehabilitation Therapy in Older Acute Heart Failure Patients, is a&#xD;
      multicenter, randomized, attention-controlled, single-blind trial designed to examine the&#xD;
      hypothesis that, in addition to standard care, a novel, tailored, progressive, multi-domain&#xD;
      rehabilitation intervention administered to older patients with acute decompensated heart&#xD;
      failure (ADHF) beginning early during hospitalization and continuing for 12 weeks will&#xD;
      improve physical function and key clinical outcomes, including the rate of rehospitalization.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There will be three lead centers, Wake Forest Baptist Health along with Thomas Jefferson&#xD;
      University and Hospital-Co-Investigator Dr. David Whellan, and Duke University Medical&#xD;
      Center-Co-Investigator Dr. Christopher O'Connor. Each center may recruit up to 3&#xD;
      geographically close, tightly affiliated 'satellite' sites under their management and&#xD;
      budgetary control. Together, these sites will recruit a total of 352 consenting patients â‰¥ 60&#xD;
      years old hospitalized with ADHF. Following informed consent and baseline testing, the&#xD;
      participants will be randomized in a 1:1 fashion to receive a 12-week novel, progressive,&#xD;
      multi-domain rehabilitation and exercise training intervention or attention control. The&#xD;
      multi-domain rehabilitation intervention will include endurance, mobility, strength, and&#xD;
      balance training and will be tailored based on participant performance in each of these&#xD;
      domains. It will begin upon randomization during the hospitalization and will continue 3&#xD;
      times per week in an outpatient setting. Participants randomized to the attention control arm&#xD;
      will receive all services ordered by their primary physician and will be contacted bi-weekly&#xD;
      by study staff. All participants will undergo measures of physical function and quality of&#xD;
      life at baseline, 1 month, and 3 months. Clinical events will be monitored for 6 months&#xD;
      following the index hospitalization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">July 27, 2020</completion_date>
  <primary_completion_date type="Actual">June 15, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Short Physical Performance Battery (SPPB) at Month 3</measure>
    <time_frame>Month 3</time_frame>
    <description>The Short Physical Performance Battery is scored on a scale of 0-12, with a higher score indicating better physical function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-Cause Rehospitalization</measure>
    <time_frame>Month 6</time_frame>
    <description>Number of all-cause rehospitalizations 6 months from index hospital discharge.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>6-minute Walk Distance</measure>
    <time_frame>Month 3</time_frame>
    <description>Exploratory outcome. Distance walked in 6 minutes.</description>
  </other_outcome>
  <other_outcome>
    <measure>Handgrip Strength</measure>
    <time_frame>Month 3</time_frame>
    <description>Exploratory outcome. Handgrip strength is measured in kilograms by a handgrip dynamometer.</description>
  </other_outcome>
  <other_outcome>
    <measure>Frailty Status (Fried Frailty Criteria) at Month 3</measure>
    <time_frame>Month 3</time_frame>
    <description>Exploratory outcome. Frailty is assessed by the Fried criteria consisting of 5 components: low physical activity, exhaustion, weakness, slowness, and unintentional weight loss. Presence of 3 or more Fried criteria indicates frailty, 1-2 criteria indicates pre-frailty, and 0 criteria indicates no frailty.</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life Measured by Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary Score</measure>
    <time_frame>Month 3</time_frame>
    <description>Exploratory outcome. The KCCQ Overall Summary Summary Score is a heart failure disease-specific quality of life measure encompassing domains of physical limitation, HF symptoms, quality of life, and social limitation scored on a scale of 0-100 with higher scores indicating better health status.</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical Limitation as Assessed by the KCCQ Physical Limitation Score</measure>
    <time_frame>Month 3</time_frame>
    <description>Exploratory outcome. The Physical Limitation Score of the KCCQ questionnaire is a subscore evaluating disease-specific physical limitation. Scores range 0-100 with a higher score indicating less physical limitation.</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life Measured by Short Form 12 Item Questionnaire (SF-12)</measure>
    <time_frame>Month 3</time_frame>
    <description>Exploratory outcome. The SF-12 is a quality of life assessment with 2 component scores (Physical Composite Score and Mental Composite Score) ranging 0-100 with higher scores indicating better health status.</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life Assessed by the EuroQol 5-dimension 5-level (EQ-5D-5L)</measure>
    <time_frame>Month 6</time_frame>
    <description>Exploratory outcome. The EQ-5D-5L is a quality of life tool with 5 components designed to detect health utilities: mobility, usual activities, self-care, pain/discomfort, and anxiety/depression. All components are rated on a scale of 1-5 with higher scores indicating worse health status.</description>
  </other_outcome>
  <other_outcome>
    <measure>Depression Measured by the Geriatric Depression Scale</measure>
    <time_frame>Month 3</time_frame>
    <description>Exploratory outcome. The Geriatric Depression Scale is a 15-item questionnaire evaluating depressive symptoms. Scores range from 0-15 with a higher score indicating more severe depressive symptoms.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cognitive Function Measured by the Montreal Cognitive Assessment (MoCA)</measure>
    <time_frame>Month 3</time_frame>
    <description>Exploratory outcome. The Montreal Cognitive Assessment is a tool for assessing multiple domains of cognitive function. Scores range 0-30 with higher scores indicating better cognitive function. A score greater than or equal to 26 is considered normal cognitive function.</description>
  </other_outcome>
  <other_outcome>
    <measure>All-cause Rehospitalizations at Month 1</measure>
    <time_frame>Month 1</time_frame>
    <description>Exploratory outcome. Number of all-cause rehospitalizations 1 month post index hospitalization discharge.</description>
  </other_outcome>
  <other_outcome>
    <measure>All-cause Rehospitalizations at Month 3</measure>
    <time_frame>Month 3</time_frame>
    <description>Exploratory outcome. Number of all-cause rehospitalizations 3 months after discharged from index hospitalization</description>
  </other_outcome>
  <other_outcome>
    <measure>All-cause Combined Rehospitalization and Death at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>Exploratory outcome. Combined number of all-cause rehospitalizations and death 6 months after discharge from index hospitalization</description>
  </other_outcome>
  <other_outcome>
    <measure>Heart Failure Rehospitalizations at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>Exploratory outcome. Number of heart failure rehospitalizations 6 months after discharge from index hospitalization</description>
  </other_outcome>
  <other_outcome>
    <measure>Hospitalization Days Post-randomization</measure>
    <time_frame>Month 6</time_frame>
    <description>Exploratory outcome. Total days spent hospitalized after date of randomization.</description>
  </other_outcome>
  <other_outcome>
    <measure>Facility-free Days Alive</measure>
    <time_frame>Month 6</time_frame>
    <description>Exploratory outcomes. Total days alive spent outside of hospital, observation unit, acute rehab setting, and skilled nursing facility 6 months after discharge from index hospitalization.</description>
  </other_outcome>
  <other_outcome>
    <measure>Emergency Department Visits</measure>
    <time_frame>Month 6</time_frame>
    <description>Exploratory outcomes. Number of emergency department visits after 6 months from hospital discharge</description>
  </other_outcome>
  <other_outcome>
    <measure>Observation Unit Stays &lt;24 Hours</measure>
    <time_frame>Month 6</time_frame>
    <description>Exploratory outcome. Number of observation unit stays &lt;24 hours 6 months after discharge from index hospitalization</description>
  </other_outcome>
  <other_outcome>
    <measure>Unscheduled Urgent Medical Visits</measure>
    <time_frame>Month 6</time_frame>
    <description>Exploratory outcome. Number of unscheduled urgent medical visits after discharge from index hospitalization</description>
  </other_outcome>
  <other_outcome>
    <measure>Global Rank Score of Short Physical Performance Battery Score + All-cause Rehospitalization + Death</measure>
    <time_frame>Month 6</time_frame>
    <description>Exploratory outcome. The global rank composite outcome combines non-commensurate endpoints including death, number of all-cause rehospitalizations, and month 3 SPPB into a single non-parametric outcome in a hierarchical manner with death being ranked first and SPPB being ranked last. Participants are ranked from the most adverse response (lowest rank) to the most favorable response (highest rank).</description>
  </other_outcome>
  <other_outcome>
    <measure>Placement at Skilled Nursing Facility</measure>
    <time_frame>Month 6</time_frame>
    <description>Exploratory outcome. Number of placements at skilled nursing facilities after discharge from index hospitalization.</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical Activity Assessed by Accelerometry</measure>
    <time_frame>Month 6</time_frame>
    <description>Exploratory outcome. Physical activity assessed by accelerometry quantified in moderate-vigorous physical activity minutes per day.</description>
  </other_outcome>
  <other_outcome>
    <measure>Generalized Optimism Assessed by the Life Orientation Test-Revised</measure>
    <time_frame>Month 3</time_frame>
    <description>Exploratory outcome. The Life Orientation Test-Revised is a assessment of generalized optimism scored on a scale of 0-24 with higher scores indicating higher optimism.</description>
  </other_outcome>
  <other_outcome>
    <measure>Economic Analysis</measure>
    <time_frame>Month 6</time_frame>
    <description>Assess direct medical costs, direct non-medical costs, indirect patient time costs, short-term cost-analysis, long-term cost analysis, and sustainability of the intervention.</description>
  </other_outcome>
  <other_outcome>
    <measure>Biomarkers</measure>
    <time_frame>Month 3</time_frame>
    <description>Two well-accepted biomarkers of HF disease severity and prognosis, NT-proBNP and galectin-3, and increased biomarkers in older HF patients Tumor necrosis factor alpha, C-reactive protein, and interleukin-6.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">349</enrollment>
  <condition>Acute Decompensated Heart Failure</condition>
  <arm_group>
    <arm_group_label>Attention Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Usual care group with bi-weekly contact from study staff</description>
  </arm_group>
  <arm_group>
    <arm_group_label>multi-domain rehabilitation intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Individual, tailored, progressive, physical function rehabilitation intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>multi-domain rehabilitation intervention</intervention_name>
    <description>Individual, tailored, progressive physical function rehabilitation intervention</description>
    <arm_group_label>multi-domain rehabilitation intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Attention Control</intervention_name>
    <description>Usual care with bi-weekly contact from study staff</description>
    <arm_group_label>Attention Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥ 60 years old&#xD;
&#xD;
          -  In the hospital setting &gt;24 hours for the management of ADHF, or diagnosed with ADHF&#xD;
             after being hospitalized for another reason. ADHF will be confirmed by the study&#xD;
             physician, and will be defined according to the Food and Drug Administration&#xD;
             definition of hospitalized heart failure as a combination of symptoms, signs, and&#xD;
             HF-specific medical treatments.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute myocardial infarction&#xD;
&#xD;
          -  Planned discharge other than to home or a facility where the participant will live&#xD;
             independently&#xD;
&#xD;
          -  Already actively participating in formal, facility-based cardiac rehabilitation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dalane W. Kitzman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University and Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 15, 2014</study_first_submitted>
  <study_first_submitted_qc>July 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2014</study_first_posted>
  <results_first_submitted>May 28, 2021</results_first_submitted>
  <results_first_submitted_qc>May 28, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 23, 2021</results_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>heart failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT02196038/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 20, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT02196038/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Attention Control</title>
          <description>Usual care group with bi-weekly contact</description>
        </group>
        <group group_id="P2">
          <title>Rehabilitation Intervention</title>
          <description>Individual, tailored, progressive, multi-domain physical function rehabilitation intervention</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="174"/>
                <participants group_id="P2" count="175"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="157"/>
                <participants group_id="P2" count="153"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Attention Control</title>
          <description>Usual care group with bi-weekly contact</description>
        </group>
        <group group_id="B2">
          <title>Rehabilitation Intervention</title>
          <description>Individual, tailored, progressive, multi-domain physical function rehabilitation intervention</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="174"/>
            <count group_id="B2" value="175"/>
            <count group_id="B3" value="349"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.2" spread="7.7"/>
                    <measurement group_id="B2" value="73.1" spread="8.5"/>
                    <measurement group_id="B3" value="72.7" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="183"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="170"/>
                    <measurement group_id="B2" value="172"/>
                    <measurement group_id="B3" value="342"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="154"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="173"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Short Physical Performance Battery</title>
          <description>The Short Physical Performance Battery is scored on a scale of 0-12, with a higher score indicating better physical function.</description>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.1" spread="2.6"/>
                    <measurement group_id="B2" value="6.0" spread="2.8"/>
                    <measurement group_id="B3" value="6.1" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Short Physical Performance Battery (SPPB) at Month 3</title>
        <description>The Short Physical Performance Battery is scored on a scale of 0-12, with a higher score indicating better physical function.</description>
        <time_frame>Month 3</time_frame>
        <population>Analysis completed on all participants alive with Month 3 SPPB obtained (n=304).</population>
        <group_list>
          <group group_id="O1">
            <title>Attention Control</title>
            <description>Usual care group with bi-weekly contact</description>
          </group>
          <group group_id="O2">
            <title>Rehabilitation Intervention</title>
            <description>Individual, tailored, progressive, multi-domain physical function rehabilitation intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Short Physical Performance Battery (SPPB) at Month 3</title>
          <description>The Short Physical Performance Battery is scored on a scale of 0-12, with a higher score indicating better physical function.</description>
          <population>Analysis completed on all participants alive with Month 3 SPPB obtained (n=304).</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="0.2"/>
                    <measurement group_id="O2" value="8.3" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>joint model</method>
            <method_desc>Joint model of ANCOVA plus survival</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All-Cause Rehospitalization</title>
        <description>Number of all-cause rehospitalizations 6 months from index hospital discharge.</description>
        <time_frame>Month 6</time_frame>
        <population>All participants, regardless of participation in the intervention or Month 3 follow-up were followed for all-cause rehospitalizations. Analysis completed on all participants, including deaths, except participants lost to follow-up (n=1) and participants withdrawn from study (n=1).</population>
        <group_list>
          <group group_id="O1">
            <title>Attention Control</title>
            <description>Usual care group with bi-weekly contact</description>
          </group>
          <group group_id="O2">
            <title>Rehabilitation Intervention</title>
            <description>Individual, tailored, progressive, multi-domain physical function rehabilitation intervention</description>
          </group>
        </group_list>
        <measure>
          <title>All-Cause Rehospitalization</title>
          <description>Number of all-cause rehospitalizations 6 months from index hospital discharge.</description>
          <population>All participants, regardless of participation in the intervention or Month 3 follow-up were followed for all-cause rehospitalizations. Analysis completed on all participants, including deaths, except participants lost to follow-up (n=1) and participants withdrawn from study (n=1).</population>
          <units>rehospitalizations</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="213"/>
                    <measurement group_id="O2" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.59</p_value>
            <method>Joint Model</method>
            <method_desc>Joint model of Poisson regression and survival</method_desc>
            <param_type>Rate Ratio</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>6-minute Walk Distance</title>
        <description>Exploratory outcome. Distance walked in 6 minutes.</description>
        <time_frame>Month 3</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Handgrip Strength</title>
        <description>Exploratory outcome. Handgrip strength is measured in kilograms by a handgrip dynamometer.</description>
        <time_frame>Month 3</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Frailty Status (Fried Frailty Criteria) at Month 3</title>
        <description>Exploratory outcome. Frailty is assessed by the Fried criteria consisting of 5 components: low physical activity, exhaustion, weakness, slowness, and unintentional weight loss. Presence of 3 or more Fried criteria indicates frailty, 1-2 criteria indicates pre-frailty, and 0 criteria indicates no frailty.</description>
        <time_frame>Month 3</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Quality of Life Measured by Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary Score</title>
        <description>Exploratory outcome. The KCCQ Overall Summary Summary Score is a heart failure disease-specific quality of life measure encompassing domains of physical limitation, HF symptoms, quality of life, and social limitation scored on a scale of 0-100 with higher scores indicating better health status.</description>
        <time_frame>Month 3</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Physical Limitation as Assessed by the KCCQ Physical Limitation Score</title>
        <description>Exploratory outcome. The Physical Limitation Score of the KCCQ questionnaire is a subscore evaluating disease-specific physical limitation. Scores range 0-100 with a higher score indicating less physical limitation.</description>
        <time_frame>Month 3</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Quality of Life Measured by Short Form 12 Item Questionnaire (SF-12)</title>
        <description>Exploratory outcome. The SF-12 is a quality of life assessment with 2 component scores (Physical Composite Score and Mental Composite Score) ranging 0-100 with higher scores indicating better health status.</description>
        <time_frame>Month 3</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Quality of Life Assessed by the EuroQol 5-dimension 5-level (EQ-5D-5L)</title>
        <description>Exploratory outcome. The EQ-5D-5L is a quality of life tool with 5 components designed to detect health utilities: mobility, usual activities, self-care, pain/discomfort, and anxiety/depression. All components are rated on a scale of 1-5 with higher scores indicating worse health status.</description>
        <time_frame>Month 6</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Depression Measured by the Geriatric Depression Scale</title>
        <description>Exploratory outcome. The Geriatric Depression Scale is a 15-item questionnaire evaluating depressive symptoms. Scores range from 0-15 with a higher score indicating more severe depressive symptoms.</description>
        <time_frame>Month 3</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cognitive Function Measured by the Montreal Cognitive Assessment (MoCA)</title>
        <description>Exploratory outcome. The Montreal Cognitive Assessment is a tool for assessing multiple domains of cognitive function. Scores range 0-30 with higher scores indicating better cognitive function. A score greater than or equal to 26 is considered normal cognitive function.</description>
        <time_frame>Month 3</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>All-cause Rehospitalizations at Month 1</title>
        <description>Exploratory outcome. Number of all-cause rehospitalizations 1 month post index hospitalization discharge.</description>
        <time_frame>Month 1</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>All-cause Rehospitalizations at Month 3</title>
        <description>Exploratory outcome. Number of all-cause rehospitalizations 3 months after discharged from index hospitalization</description>
        <time_frame>Month 3</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>All-cause Combined Rehospitalization and Death at Month 6</title>
        <description>Exploratory outcome. Combined number of all-cause rehospitalizations and death 6 months after discharge from index hospitalization</description>
        <time_frame>Month 6</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Heart Failure Rehospitalizations at Month 6</title>
        <description>Exploratory outcome. Number of heart failure rehospitalizations 6 months after discharge from index hospitalization</description>
        <time_frame>Month 6</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Hospitalization Days Post-randomization</title>
        <description>Exploratory outcome. Total days spent hospitalized after date of randomization.</description>
        <time_frame>Month 6</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Facility-free Days Alive</title>
        <description>Exploratory outcomes. Total days alive spent outside of hospital, observation unit, acute rehab setting, and skilled nursing facility 6 months after discharge from index hospitalization.</description>
        <time_frame>Month 6</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Emergency Department Visits</title>
        <description>Exploratory outcomes. Number of emergency department visits after 6 months from hospital discharge</description>
        <time_frame>Month 6</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Observation Unit Stays &lt;24 Hours</title>
        <description>Exploratory outcome. Number of observation unit stays &lt;24 hours 6 months after discharge from index hospitalization</description>
        <time_frame>Month 6</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Unscheduled Urgent Medical Visits</title>
        <description>Exploratory outcome. Number of unscheduled urgent medical visits after discharge from index hospitalization</description>
        <time_frame>Month 6</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Global Rank Score of Short Physical Performance Battery Score + All-cause Rehospitalization + Death</title>
        <description>Exploratory outcome. The global rank composite outcome combines non-commensurate endpoints including death, number of all-cause rehospitalizations, and month 3 SPPB into a single non-parametric outcome in a hierarchical manner with death being ranked first and SPPB being ranked last. Participants are ranked from the most adverse response (lowest rank) to the most favorable response (highest rank).</description>
        <time_frame>Month 6</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Placement at Skilled Nursing Facility</title>
        <description>Exploratory outcome. Number of placements at skilled nursing facilities after discharge from index hospitalization.</description>
        <time_frame>Month 6</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Physical Activity Assessed by Accelerometry</title>
        <description>Exploratory outcome. Physical activity assessed by accelerometry quantified in moderate-vigorous physical activity minutes per day.</description>
        <time_frame>Month 6</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Generalized Optimism Assessed by the Life Orientation Test-Revised</title>
        <description>Exploratory outcome. The Life Orientation Test-Revised is a assessment of generalized optimism scored on a scale of 0-24 with higher scores indicating higher optimism.</description>
        <time_frame>Month 3</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Economic Analysis</title>
        <description>Assess direct medical costs, direct non-medical costs, indirect patient time costs, short-term cost-analysis, long-term cost analysis, and sustainability of the intervention.</description>
        <time_frame>Month 6</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Biomarkers</title>
        <description>Two well-accepted biomarkers of HF disease severity and prognosis, NT-proBNP and galectin-3, and increased biomarkers in older HF patients Tumor necrosis factor alpha, C-reactive protein, and interleukin-6.</description>
        <time_frame>Month 3</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs collected from date of discharge from index hospitalization through Month 6.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Attention Control</title>
          <description>Usual care group with bi-weekly contact</description>
        </group>
        <group group_id="E2">
          <title>Rehabilitation Intervention</title>
          <description>Individual, tailored, progressive, multi-domain physical function rehabilitation intervention</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="115" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="106" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>epitaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>leukocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>aortic valve disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>atrial flutter</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="174"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="174"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>heart failure exacerbation</sub_title>
                <counts group_id="E1" events="107" subjects_affected="64" subjects_at_risk="174"/>
                <counts group_id="E2" events="99" subjects_affected="57" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>mitral stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>mitral valve repair</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>myocardial infarction</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="174"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>sudden cardiac death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="174"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>ventricular tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>colonic fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="174"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>duodenal ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="174"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>gastrointestinal bleed</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="174"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>gastroparesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>inguinal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>multiple organ failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>small bowel obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="174"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>hepatotoxicity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>liver cirrhosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>primary amyloidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>bacterial endocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>osteomyelitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>upper respiratory infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="174"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>injurious fall</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="174"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>intracranial hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>oxycontin overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>serotonin syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>spinal compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>tacrolimus toxicity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>hypoglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>gout flare</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="174"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>chronic lymphocytic leukemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>metastatic cancer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="174"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>pancreatic adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dysarthia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>stroke</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="174"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>syncope</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="174"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>transient ischemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>sucidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>acute kidney injury</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="174"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>hematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>vaginal discharge</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COPD exacerbation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="174"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="174"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>interstitial lung disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>pleural effusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="174"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>pulmonary edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>respiratory failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>diabetic foot ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>ablation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="174"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>arteriovenous fistula placement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>bronchoscopy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>cateract surgery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>implantable cardioverter defibrillator implantation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>pacemaker implantation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>remodulin pump implantation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>renal artery angioplasty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="174"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>elevated international normalized ratio</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>epitaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>heart failure exacerbation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="174"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>suprventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>sudden vision loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>gastrointestinal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="174"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>melena</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="174"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>upper respiratory infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="174"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>abrasion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>ear injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>fall (self-reported)</sub_title>
                <counts group_id="E1" events="112" subjects_affected="62" subjects_at_risk="174"/>
                <counts group_id="E2" events="94" subjects_affected="48" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>foot wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>ICD device complications</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>inguinal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>post-prodecural complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>fluid retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>hypoglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>gout flare</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="174"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>muscle strain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>musculoskeletal pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="174"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>altered mental status</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="174"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>acute kidney injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>elevated creatinine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>hematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>kidney stone</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>urinary retention</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="174"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COPD exacerbation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="174"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>skin lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>venous stasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Dalane Kitzman</name_or_title>
      <organization>Wake Forest School of Medicine</organization>
      <phone>336-716-3274</phone>
      <email>dkitzman@wakehealth.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

